Clinical trials

Condition   Drug Name  
Study Efalizumab in psoriasis
Design Open
Patients 15
Treatment Regimen Efalizumab, 0.7 mg/kg/wk s.c. x 1 wk --> 1 mg/kg/wk
Conclusions Efalizumab significantly reduced psoriatic lesions
Reference(s) Treatment of moderate to severe psoriasis with efalizumab: A six month follow up
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1052.
Author and Affiliation Solovan, C.S., Radivoi, D., Ciolan, M.